Comparative Pharmacology
Head-to-head clinical analysis: BEXAROTENE versus VESANOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BEXAROTENE versus VESANOID.
BEXAROTENE vs VESANOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective retinoid X receptor (RXR) agonist; modulates gene expression involved in cell differentiation and apoptosis.
Retinoic acid receptor (RAR) agonist, inducing differentiation and apoptosis of acute promyelocytic leukemia (APL) cells.
300 mg/m2 orally once daily on days 1 through 28 of a 28-day cycle for cutaneous T-cell lymphoma.
45 mg/m2/day orally divided into two equal doses. Administer with food.
None Documented
None Documented
Terminal elimination half-life is approximately 7 hours in patients with cutaneous T-cell lymphoma; no significant accumulation with repeated dosing.
Clinical Note
moderateBexarotene + Digoxin
"Bexarotene may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateBexarotene + Digitoxin
"Bexarotene may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateBexarotene + Deslanoside
"Bexarotene may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateBexarotene + Acetyldigitoxin
"Bexarotene may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life approximately 40-50 hours in adults; clinical context: steady state achieved after 7-10 days of continuous dosing.
Primarily metabolized in the liver via CYP3A4; metabolites are excreted in feces (approximately 70%) and urine (approximately 10%). Less than 1% of unchanged drug is excreted in urine.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <15% of dose; biliary/fecal excretion accounts for >85% of dose as metabolites.
Category C
Category C
Retinoid Antineoplastic
Retinoid Antineoplastic